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oSBACKGROUND Results of the SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) trial
conﬁrmed the safety but not the efﬁcacy of renal denervation for treatment-resistant hypertension at 6 months post
procedure.
OBJECTIVES This study sought to analyze the 12-month SYMPLICITY HTN-3 results for the original denervation group,
the sham subjects who underwent denervation after the 6-month endpoint (crossover group), and the sham subjects who
did not undergo denervation after 6 months (non-crossover group).
METHODS Eligible subjects were randomized 2:1 to denervation or sham procedure. Subjects were unblinded to their
treatment group after the 6-month primary endpoint was ascertained; subjects in the sham group meeting eligibility
requirements could undergo denervation. Change in blood pressure (BP) at 12 months post randomization (6 months for
crossover subjects) was analyzed.
RESULTS The 12-month follow-up was available for 319 of 361 denervation subjects and 48 of 101 non-crossover
subjects; 6-month denervation follow-up was available for 93 of 101 crossover subjects. In denervation subjects, the
12-month ofﬁce systolic BP (SBP) change was greater than that observed at 6 months (15.5  24.1 mm Hg vs. 18.9 
25.4 mm Hg, respectively; p ¼ 0.025), but the 24-h SBP change was not signiﬁcantly different at 12 months (p ¼ 0.229).
The non-crossover group ofﬁce SBP decreased by 32.9  28.1 mm Hg at 6 months, but this response regressed
to 21.4  19.9 mm Hg (p ¼ 0.01) at 12 months, increasing to 11.5  29.8 mm Hg.
CONCLUSIONS These data support no further reduction in ofﬁce or ambulatory BP after 1-year follow-up. Loss of
BP reduction in the non-crossover group may reﬂect decreased medication adherence or other related factors. (Renal
Denervation in Patients With Uncontrolled Hypertension [SYMPLICITY HTN-3]; NCT01418261) (J Am Coll Cardiol
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1315AB BR E V I A T I O N S
AND ACRONYM S
ABPM = ambulatory blood
pressure monitoring
DBP = diastolic blood pressure
SBP = systolic blood pressureT he SYMPLICITY HTN-3 (Renal Denervation inPatients With Uncontrolled Hypertension)study was a prospective, blinded, random-
ized, sham-controlled trial that used ambulatory
blood pressure measurement (ABPM) as part of the
inclusion criteria as well as a pre-speciﬁed secondary
endpoint. All participants were evaluated at baseline
and 6 months for changes in ambulatory, home, and
ofﬁce blood pressure (BP). Primary results of the trialSEE PAGE 1322demonstrated safety of the renal denervation proce-
dure but failed to show a greater reduction in ofﬁce
or ambulatory systolic BP (SBP) than that with the
sham procedure at 6 months (1). This paper presents
the detailed ofﬁce and 24-h ABPM results of SYM-
PLICITY HTN-3 after 1 year of follow-up in the orig-
inal cohort randomized to the procedure as well as
in those who were either not eligible to be crossed
over and those who were crossed over and who un-
derwent renal denervation at 6 months.
METHODS
STUDY POPULATION. SYMPLICITY HTN-3 was a
prospective, randomized, sham-controlled, multi-
center clinical trial. Primary results and detailed
methods were published previously (1). Adult sub-
jects with uncontrolled hypertension receiving a
stable antihypertensive medication regimen that
included maximally tolerated doses of $3 medica-
tions of complementary classes, including a diuretic
agent, were randomized 2:1 to undergo renal dener-
vation or sham procedure. Subjects were required to
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to ablate surrounding efferent and afferent nerves.
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1316ENDPOINTS. The primary efﬁcacy and safety endpoints
have been previously described and published (1).
Blood pressure changes from baseline (before ran-
domization) to 6- and 12-month follow-up are
now reported for subjects in the denervation and
non-crossover groups. The BP changes from pre-
procedure baseline (6-month post-original randomi-
zation) to 6months following denervation are reported
for the crossover group. All denervated subjects
(denervation and crossover groups) were followed
biannually, and non-crossover subjects were followed
annually through 5 years post-randomization. An
interim protocol amendment added 12-month ABPM
for non-crossover subjects; thus, these data were
available only for those who consented.
STATISTICAL ANALYSES. Analyses were performed
on the basis of intent-to-treat principle. Means and
standard deviations (SD) of continuous variables were
presented by treatment group. Variations in ambula-
tory BP at each visit were deﬁned as SD or coefﬁcient
of variation (the SD/mean ratio). Between-group dif-
ferences were compared using conﬁdence intervals
(CIs) and tested using unpaired Student t tests.
Within-group differences from baseline to follow-up
were tested using paired Student t tests. For cate-
gorical variables, counts and percentages were pre-
sented by treatment group and tested using the exact
test for binary variables and chi-square test for
multilevel categorical variables.FIGURE 1 Patient Disposition: 6 Months to 1 Year
Crossove
101 Subjec
Denervation group
361 Subjects
4 Died
3 Withdrew
354 Eligible for
12–month follow–up
96 Eligible 
6–month post–RDN
93 Subjects (9
6–month post–RDN
322* Subjects (91%)
12–month follow–up
*319 had both 6– and 12–month follow–up
All subjects were unblinded after the 6-month primary endpoint. Sham-c
the crossover group, and subjects not denervated formed the non-crossROLE OF FUNDING SOURCE. The trial was designed
by the coprincipal investigators and the sponsor,
Medtronic, Inc. Data were collected and analyzed
by the sponsor and independently validated by Har-
vard Clinical Research Institute (Boston, Massachu-
setts). The lead author wrote the ﬁrst draft of the
manuscript, and all coauthors contributed and
approved the ﬁnal manuscript. The corresponding
author had full access to all study data and had ﬁnal
responsibility for the decision to submit.
RESULTS
After unblinding, 101 sham subjects who met eligi-
bility requirements chose to undergo renal denerva-
tion, thus forming the crossover group; the remaining
70 patients, including 6 subjects who were eligible
but declined the procedure, comprised the non-
crossover group (Figure 1). The 6- and 12-month
follow-up data were available for 319 subjects from
the original denervation group and 48 subjects from
the non-crossover group. Crossover subjects (n ¼ 93)
had 6 months of follow-up from the time of the
denervation procedure. Baseline characteristics and
antihypertensive medication used were similar across
the 3 groups, although there were more men and
more African-American subjects in the non-crossover
group (Table 1). The non-crossover group also had
signiﬁcantly lower baseline pressure values thanSham control group
171 Subjects
Non–Crossover
70 Subjects
r
ts
2 Died
3 Withdrew
2 Died
6 Withdrew
for
 follow–up
6.9%)
 follow–up
62 Eligible for
12–month follow–up
48 Subjects (77%)
12–month follow–up
ontrol subjects receiving renal denervation (RDN) at 6 months formed
over group.
TABLE 1 Baseline Characteristics of the Study Population*
Denervation
Group
(n ¼ 364)
Crossover
Group
(n ¼ 101)
Non-Crossover
Group
(n ¼ 70) p Value
Age, yrs 57.9  10.4 55.2  10.7 57.7  11.8 0.076
Male 215 (59.1%) 63 (62.4%) 47 (67.1%) 0.189
BMI, kg/m2 34.2  6.5 33.9  6.4 35.2  7.8 0.076
Race 0.678
Black 90 (24.8%) 28 (27.7%) 22 (31.4%)
White 265 (73.0%) 119 (69.6%) 47 (67.1%)
Other 8 (2.3%) 2 (1.2%) 1 (1.4%)
Medical history
Renal insufﬁciency
(eGFR <60 ml/min/1.73 m2)
34 (9.3%) 10 (9.9%) 7 (10.0%) 0.906
Coronary artery disease 101 (27.7%) 28 (27.7%) 16 (22.9%) 0.469
Type 2 diabetes 171 (47.0%) 38 (37.6%) 32 (45.7%) 0.425
24-h heart rate, beats/min 70.2  14.4 70.3  16.3 69.9  13.2
Number of BP-lowering medications 5.1  1.4 5.2  1.6 5.2  1.4
ACE inhibitors 179 (49.2%) 47 (46.5%) 26 (37.1%)
Angiotensin receptor blockers 182 (50.0%) 50 (49.5%) 39 (55.7%)
Aldosterone antagonists 82 (22.5%) 29 (28.7%) 21 (30.0%)
Alpha-adrenergic blockers 40 (11.0%) 11 (10.9%) 11 (15.7%)
Beta blockers 310 (85.2%) 88 (87.1%) 59 (84.3%)
Calcium channel blockers 254 (69.8%) 76 (75.2%) 50 (71.4%)
Centrally acting sympatholytic
agents
179 (49.2%) 42 (41.6%) 35 (50.0%)
Diuretics 363 (99.7%) 100 (99.0%) 70 (100%)
Direct renin inhibitors 26 (7.1%) 8 (7.9%) 5 (7.1%)
Direct-acting vasodilators 134 (36.8%) 44 (43.6%) 29 (41.4%)
Values are mean  SD or n (%). *All differences in characteristics between groups are nonsigniﬁcant.
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; BP ¼ blood pressure; eGFR ¼ estimated
glomerular ﬁltration rate.
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1317the crossover subjects (176.1  14.9 mm Hg vs. 183.9 
19.1 mm Hg, respectively; p ¼ 0.003).
Changes from pre-procedure baseline BP from
ofﬁce to 24-h ambulatory BP are displayed in the
Central Illustration for the denervation and cross-
over subjects. The 12-month changes in ofﬁce SBP
were signiﬁcantly greater than those observed at
the 6-month visit for the denervation group (15.5
 24.1 vs. 18.9  25.4, respectively; p ¼ 0.025)
(Central Illustration A). However, there were no
signiﬁcant differences between 6- and 12-month
ABPM changes (Central Illustration B). The cross-
over group baseline BP was on the basis of pre-
procedure measurements at the 6-month crossover
time point. The 6-month drop in ofﬁce SBP in the
crossover group was 17.7  23.2 mm Hg (p < 0.001
from baseline), and the 6-month drop in 24-h
SBP was 9.2  13.6 mm Hg (p < 0.001 from
baseline).
The non-crossover group had a mean ofﬁce BP
(systolic/diastolic) of 145.6  24.6/82.9  13.4 mm Hg
at 6 months, indicating that for many of these sub-
jects (64 of 70 [91.4%]), their ineligibility for renal
denervation at 6 months was due to not meeting the
SBP minimum of 160 mm Hg. Changes in ofﬁce BP at 6
and 12 months for the non-crossover subjects with 12-
month data available (n ¼ 48) showed a very large
SBP change from baseline to 6 months (32.9  28.1
mm Hg) with some loss of effect (an increase in SBP of
11.5  29.8 mm Hg) between 6 and 12 months (p ¼ 0.01
for the differences in 6- and 12-month SBPs) for an
overall SBP drop from baseline of 21.4  19.9 mm Hg
at 12 months (Figure 2A).
Ambulatory data were available for only 20 of 70
non-crossover subjects (29%) at 12 months, given that
ABPM was not protocol-mandated for these subjects
at this time point. However, in these 20 subjects, a
pattern similar to that of ofﬁce readings was observed
showing a larger 24-h BP reduction at 6 months
compared with 12 months (11.0  19.5 mm Hg at
6 months versus 6.1  14.4 mm Hg at 12 months;
p ¼ 0.272) (Figure 2B).
Composite safety data are summarized in Table 2.
The safety measures were similar between 6 and
12 months among the 3 groups. One subject from the
denervation group developed end-stage renal dis-
ease. The patient had a history of obesity, obstructive
sleep apnea, diabetes mellitus type 2, renal insufﬁ-
ciency (baseline estimated glomerular ﬁltration rate
of 46 ml/min/1.73 m2), left ventricular hypertrophy,
coronary artery disease, and myocardial infarction.
Approximately 7 months post-denervation, he was
admitted with weakness, progressive uremic symp-
toms, and shortness of breath. His serum creatinineconcentration increased to 4.0 mg/dl, and hemodial-
ysis was initiated.
DISCUSSION
The 1-year follow-up data for the SYMPLICITY HTN-3
trial reafﬁrm results of the 6-month data with regard
to primary and speciﬁed secondary endpoints and
indicate different BP responses in different groups
following unblinding at 6 months. There was a
small but signiﬁcant additional drop in ofﬁce BP at
12months but no further signiﬁcant reduction in ABPM
at 12 months in subjects originally randomized to un-
dergo renal denervation. Sham subjects who crossed
over to renal denervation after the 6-month primary
endpoint had a decrease in SBP 6 months following
the procedure similar to those who originally under-
went denervation (Central Illustration). More striking
was the signiﬁcant loss of BP control at 1 year in the
non-crossover group, manifested by decreased BP
reduction in both ofﬁce and ambulatory readings. Last,
the safety proﬁle continued from that seen at 6months.
A review of subject characteristics among the 3
groups demonstrated no differences in follow-up of
CENTRAL ILLUSTRATION Change in Blood Pressure With Denervation
Ofﬁce (A) and 24-h ambulatory (B) blood pressure changes are shown for the originally denervated subjects and the crossover subjects denervated at 6 months
after being unblinded. The 6-month change from pre-procedure baseline is shown for the crossover subjects. Although ambulatory pressures remained essentially
unchanged, there was a small but signiﬁcant additional drop in ofﬁce BP at 1 year. DBP ¼ diastolic blood pressure; RDN ¼ renal denervation; SBP ¼ systolic blood
pressure.
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FIGURE 2 Non-Crossover Group: Blood Pressure Changes at 6 and 12 Months
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Ofﬁce (A) and 24-h ambulatory (B) BP changes at 6 and 12 months are shown for subjects
who were unblinded at 6 months but did not go on to receive renal denervation. As with
those receiving RDN, the changes were signiﬁcant for ofﬁce readings but not for ambu-
latory measurements. DBP ¼ diastolic blood pressure; SBP ¼ systolic blood pressure; other
abbreviations as in Figure 1.
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1319subgroups thought to detract from the effects of renal
denervation in the 6-month primary analyses, such as
race or older age (>65 years of age) of subjects (1). At
1 year, we found no differences in proportion of
African Americans, which ranged from 25% to 31%,
among groups. Likewise, there were no differences
among the proportions of people 65 years of age and
older in any single group.
There were no differences in safety outcomes
among the groups, and this included progression to
end-stage kidney failure or cardiovascular-associated
deaths. Moreover, there were no differences in epi-
sodes of hypertensive urgency or emergency. There
was 1 subject from the initial denervation group,
however, who developed end-stage renal disease
requiring chronic dialysis therapy, but that subject
entered the trial with stage 3 chronic kidney disease.
Why these results differ from earlier SYMPLICITY
trial follow-up data at 1 year is unclear. Of course, it
may have to do with the more rigorous trial meth-
odology of SYMPLICITY HTN-3 (blinding, sham con-
trol, and other factors). There are other potential
explanations for these results, the 2 most prominent
being an increase in early medication adherence that
decreased over time (although it is unclear why this
would differ among arms) as well as a failure to pro-
vide complete denervation in the renal arteries using
a predeﬁned pattern (3). Recent preclinical data sup-
port the concept that all main renal arteries as well as
distal segments of the main renal arteries and, when
feasible, the arterial branch vessels and accessory
arteries should be targeted for complete denervation
(4).
Another possible factor is the Hawthorne effect
that was expressed initially as strong patient adher-
ence to medications (5). The improved adherence to
medications in the group that initially or subse-
quently received the procedure is seen at 1 year with
similar BP reductions. In contrast, the non-crossover
group had a signiﬁcant loss in BP control following
unblinding compared with that in the denervated
groups, a result that may relate to reduced medica-
tion adherence. These results are consistent with
known factors impacting medication adherence such
as medication complexity, social support, and lack of
clear beneﬁt in chronic disease (6).
Additionally, a less likely scenario is the statistical
phenomenon, regression to the mean, in which mul-
tiple measurements tend to return to a true mean (7).
This has been suggested as a possible explanation
for the observed results and highlights the impor-
tance of continued follow-up of all subjects to docu-
ment BP trajectory. The signiﬁcant reduction in ofﬁce
SBP between 6 and 12 months that is not seen with24-h ambulatory SBP over the same period may be
consistent with a reduction in the white coat effect. A
study examining the relationship over time between
ofﬁce and ambulatory BP in 2,722 patients found that
the differences between ofﬁce and ambulatory BP
measurements, termed the “white coat effect,” were
less at 1-year follow-up after intensive pharmaco-
therapy (8). The degree of BP change was related to
the pretreatment BP level that has also been consis-
tently observed in the renal denervation trials (3,9).
The current trial required a baseline ambulatory SBP
TABLE 2 Safety at 6- and 12-Month Follow-Up
Parameter
Denervation
(n ¼ 364)
Crossover*
(n ¼ 101)
Non-
Crossover
(n ¼ 70)
To 6 months
Composite safety to
6 months
3.6
(13/358)
5.2
(5/96)
2.9
(2/70)
Death 0.6 2.1 1.4
New-onset end-stage renal
disease
0.0 0.0 0.0
Signiﬁcant embolic event
resulting in end-organ
damage
0.3 0.0 0.0
Vascular complication 0.3 0.0 0.0
Renal artery reintervention 0.0 0.0 0.0
Hypertensive crisis/emergency 2.5 3.1 1.4
New renal artery stenosis
> 70%
0.0 0.0 0.0
To 12 months
Composite safety to
12 months
6.8%
(24/355)
5.3%
(5/95)
7.2%
(5/69)
Death 1.8 NA 3.6
New-onset end-stage renal
disease
0.3 NA 0.0
Signiﬁcant embolic event
resulting in end-organ
damage
0.3 NA 0.0
Vascular complication 0.3 NA 0.0
Renal artery reintervention 0.6 NA 0.0
Hypertensive crisis/emergency 4.8 NA 5.5
New renal artery stenosis
>70%
NA† NA 0.0
Values are % unless otherwise indicated. *Safety from time of crossover
procedure. †Not assessed at 12 months.
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white coat-resistant hypertension; however, differ-
ences in the mean baseline SBPs taken in the ofﬁce
versus those by ABPM were 20.6  16.1 mm Hg for the
denervation group. This may indicate that white coat-
resistant hypertension was not entirely eliminated
from the study population. This difference was only
9.2  18.9 mm Hg at 12 months, which is consistent
with the observation of less white coat effect after
intensive treatment; a similar smaller white coat
effect was also observed in the untreated non-
crossover group (20.9  17.0 mm Hg SBP at baseline
and 10.1  16.5 mm Hg at 12 months).
Finally, in the SYMPLICITY HTN-1 trial, BP
continued to drop over 3 years of follow-up following
renal denervation (9). The small but signiﬁcant
increase in BP change seen at 12 months for the
denervation group in the current trial was not dupli-
cated in the ABPM data, but longer follow-up may
clarify whether these early observations will be
meaningful.
A second randomized, blinded, sham-controlled
trial of renal denervation in patients with lesssevere hypertension also did not show a signiﬁcant
beneﬁt of denervation in the intent-to-treat popula-
tion at 6 months (10). That study had a number of
limitations, including a small sample size and
2 patients allocated to the wrong treatment group,
but it conﬁrmed the importance of a sham control for
future clinical trials of renal denervation.
STUDY LIMITATIONS. Limitations of this analysis
include incomplete follow-up in patients in the non-
crossover group due primarily to withdrawal of con-
sent (n ¼ 6) and missed visits at 12 months (n ¼ 14).
Thus, the observations in that group need to be
interpreted cautiously. The safety of renal denerva-
tion beyond 12 months was not addressed in the
present analysis, however, longer-term follow-up is
ongoing.
CONCLUSIONS
This further analysis of data from SYMPLICITY HTN-3
demonstrates a further reduction in ofﬁce BP at 12
months, but renal denervation failed to reduce 24-h
ambulatory BP to a greater extent at 1 year than at
6 months. There was no difference in the safety pro-
ﬁle among the groups. As a result of further detailed
research into the renal denervation process itself and
the evaluation of medication adherence, we conclude
that renal denervation is safe but, by the method
applied in SYMPLICITY HTN-3, does not clearly
reduce BP to a greater extent than medication. Future
randomized, blinded, and sham-controlled studies
will be necessary to determine if renal denervation
performed differently will provide substantial BP
reduction.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Renal
denervation did not lower BP more than a sham procedure
plus medication in subjects with resistant hypertension
after 12 months in the SYMPLICITY HTN-3 clinical trial.
COMPETENCY IN PATIENT CARE: Renal denervation
as used in this trial is not approved for clinical use in
patients with resistant hypertension.
TRANSLATIONAL OUTLOOK: More research is
needed to clarify whether other renal denervation
techniques could be more effective than adherence to
medication therapy in patients with hypertension.
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